Keywords
Carcinoid Syndrome
Diagnosis
Therapeutics
Consensus
Colombia
How to Cite
Abstract
Background: Intestinal neuroendocrine tumors (NET) develop from specialized cells of the diffuse endocrine system, and may have the ability to excessively release serotonin and other vasoactive peptides, causing symptoms that are collectively called carcinoid syndrome. Intestinal NETs are heterogeneous in their biology and clinical course, histopathological diagnosis offers challenges for pathologists and the images required for staging and follow-up have technical particularities, added to the limited availability of some of them. Furthermore, due to its low incidence, the possibilities of clinical suspicion in primary care centers are reduced, often causing a delay in diagnosis. All of these factors make the path to diagnosis and treatment decisions complex.
Purpose: To define the criteria for the diagnosis, treatment, and follow-up of secretory intestinal NETs in Colombia.
Methodology: A modified Delphi-type consensus was performed. A panel of Colombian medical experts in the management of neuroendocrine pathologies was chosen. The results were analyzed and discussed, and based on reaching consensus, the conclusions of the recommendations within different aspects related to secretory intestinal NETs were summarized.
Results: Recommendations were obtained for the management of patients with secretory intestinal NETs and carcinoid syndrome in Colombia, including clinical suspicion, diagnosis, treatment, and follow-up.
Conclusions: In Colombia, it is important to reduce variability in daily clinical practice, as well as strengthening the knowledge of healthcare professionals, from the primary care setting to referral care, regarding the diagnosis, treatment and follow-up of patients with secretory intestinal NETs and carcinoid syndrome, with the aim of providing timely and adequate management of the disease.
References
Carrillo D, Muñoz-Medel M, Retamal I, Pinto M, Bravo ML, Nervi B, et al. Tumores neuroendocrinos: un desafío transversal. Rev Méd Chile. 2021;149(6):888-98. http://dx.doi.org/10.4067/s0034-98872021000600888
Bednarczuk T, Zemczak A, Bolanowski M, Borowska M, Chmielik E, ?wik?a JB, et al. Neuroendocrine neoplasms of the small intestine and the appendix - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022;73(3):549-83. https://doi.org/10.5603/EP.a2022.0052
Krishnan M, Tuma F. Intestinal carcinoid cancer. En: StatPearls [internet]. Treasure Island, Florida: StatPearls Publishing; 2023 [citado 2023 nov. 16]. http://www.ncbi.nlm.nih.gov/books/NBK448121/
Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol. 2018;6(5):404-15. https://doi.org/10.1016/s2213-8587(17)30401-1
Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110(6):444-76. https://doi.org/10.1159/000503721
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471-87. https://doi.org/10.3322/caac.21493
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115-54. https://doi.org/10.1007/s12022-022-09708-2
Grozinsky?Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, et al. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J Neuroendocrinol. 2022;34(7):e13146. https://doi.org/10.1111/jne.13146
Clement D, Ramage J, Srirajaskanthan R. Update on pathophysiology, treatment, and complications of carcinoid syndrome. J Oncol. 2020;2020:8341426. https://doi.org/10.1155/2020/8341426
Fierro-Maya LF, Prieto C, Garavito-G G, González-C AM, Muleth Y, Carreño JA. Resultados del tratamiento multidisciplinario de tumores neuroendocrinos de intestino delgado. Rev Colomb Cancerol. 2018;22(3):105-11.
Wolin EM, Benson III AB. Systemic treatment options for carcinoid syndrome: a systematic review. Oncology. 2019;96(6):273-89. https://doi.org/10.1159/000499049
Cuyle PJ, Geboes K, Carton S, Casneuf V, Decaestecker J, De Man M, et al. Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified Delphi method. Acta Gastroenterol Belg. 2020;83(4):643-53.
Ma X, Ding Y, Li W, Li Q, Yang H. Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: update and future perspective. Front Oncol. 2022;12:1061065. https://doi.org/10.3389/fonc.2022.1061065
Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14(8):471-82. https://doi.org/10.1200/jop.18.00135
Romero-Collado A. Elementos esenciales para elaborar un estudio con el método (e)Delphi. Enferm Intensiva. 2021;32(2):100-4. https://doi.org/10.1016/j.enfie.2020.09.003
Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine. 2023;102(7):e32829. https://doi.org/10.1097/md.0000000000032829
Donohoe H, Stellefson M, Tennant B. Advantages and limitations of the e-Delphi technique: implications for health education researchers. Am J Health Educ. 2012;43(1):38-46. http://dx.doi.org/10.1080/19325037.2012.10599216
García Valdés M, Suárez Marín M. El método Delphi para la consulta a expertos en la investigación científica. Rev Cubana Salud Pública. 2013;39(2):253-67.
Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684-706. https://doi.org/10.1177/0269216317690685
van Zuuren EJ, Logullo P, Price A, Fedorowicz Z, Hughes EL, Gattrell WT. Existing guidance on reporting of consensus methodology: a systematic review to inform ACCORD guideline development. BMJ Open. 2022;12(9):e065154. https://doi.org/10.1136/bmjopen-2022-065154
Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930-6. https://doi.org/10.1634/theoncologist.2014-0120
Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14-23. https://doi.org/10.1200/jco.2016.69.2780
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-35. https://doi.org/10.1056/nejmoa1607427
Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075-86. https://doi.org/10.2147/dddt.s84177
Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer. 2019;26(3):R145-56. https://doi.org/10.1530/erc-18-0495
Arnold R, Rinke A, Klose KJ, Müller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761-71. https://doi.org/10.1016/s1542-3565(05)00481-7
Lee L, Ito T, Jensen RT. Everolimus in treatment of neuroendocrine tumors: efficacy, side-effects, resistance and factors affecting its place in the treatment sequence. Expert Opin Pharmacother. 2018;19(8):909-28. https://doi.org/10.1080/14656566.2018.1476492
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-12. https://doi.org/10.1016/s0140-6736(11)61742-x
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-60. https://doi.org/10.1016/j.annonc.2020.03.304
Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, et al. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol. 2018;4(11):1597-604. https://doi.org/10.1001/jamaoncol.2018.2428
Khan MS, Walter T, Buchanan-Hughes A, Worthington E, Keeber L, Feuilly M, et al. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: a systematic review. World J Gastroenterol. 2020;26(30):4537-56. https://doi.org/10.3748/wjg.v26.i30.4537
de Celis Ferrari ACR, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics. 2018;73(supl. 1):e490s. https://doi.org/10.6061/clinics/2018/e490s
Baron T, Bergsten J, Albåge A, Lundin L, Sörensen J, Öberg K, et al. Cardiac imaging in carcinoid heart disease. JACC Cardiovasc Imaging. 2021;14(11):2240-53. https://doi.org/10.1016/j.jcmg.2020.12.030
P?czkowska M, Konsek-Komorowska SJ, Kolasi?ska-?wik?a AD, Konka M, Micha?owska I, ?wik?a JB. What do we know about carcinoid heart disease in the present era? Kardiol Pol. 2022;80(10):990-1001. https://doi.org/10.33963/KP.a2022.0222
Trikalinos NA, Hammill C, Liu J, Navale P, Winter K, Chatterjee D, et al. Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms. Abdom Radiol. 2022;47(12):4096-102. https://doi.org/10.1007/s00261-022-03707-x
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Revista Colombiana de Endocrinología, Diabetes & Metabolismo